Investors hope Zale
What analysts say:
- Buy, sell, or hold?: Analysts think investors should stand pat on Zale with three of four analysts rating it hold. Analysts like Zale better than competitor Blue Nile overall. One out of 11 analysts rate Blue Nile a buy compared to one of four for Zale. Analysts still rate the stock a hold, but they are a bit more wary about it compared to three months ago.
- Revenue Forecasts: On average, analysts predict $338.6 million in revenue this quarter. That would represent a rise of 3.5% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is a loss of $1.42 per share. Estimates range from a loss of $1.54 to a loss of $1.34.
What our community says:
Most CAPS All-Stars are skeptical of Zale's prospects, with 68.8% giving it an "underperform" rating. The community is of two minds on the stock with 46% Fools awarding it an "outperform" rating and 54% an "underperform" rating. Fools are bearish on Zale and haven't been shy with their opinions lately, logging 203 posts in the past 30 days. Zale's bearish CAPS rating of one out of five stars falls short of the Fool community sentiment.
Revenue has now gone up for three straight quarters.
For all our Zale-specific analysis, including earnings and beyond, add Zale to My Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.